I'm not knocking your opinion, but I'd like to know why you feel that way. IND filing and 20 million funding in April (to be bought by way of stock purchase) has us easily headed toward a nickel. FDA-approval would put us over a dime in no time considering the opportunities that would open up. Even if by chance it were denied, that doesn't symbolize the end of the road. The FDA just points out mistakes and BMSN would revise and resubmit. IND application approval and Phase 1 (70% success rate) is the easy part. Though if you're long then you'd know our chances of approval are good when taking the people involved into account (Cromos Pharma, Cook Biotechnology, and Medistem; that we know of.) And lets not forget about the recent push by the FDA to accelerate the approval and clinical trial process. Don't underestimate the power of market mentality in biotechs. Many signs point north.
PS: To your more recent question, we're at a penny because HemaXellerate I(TM) wasn't the main focus from the git-go. Frankly, they had troubles in the past with having a solid direction, and I truly believe they have found it. Unless a biotech has a product already on the market, they rarely thrive on financials. They often rely on funding. That's why they are popular; because one piece of success can turn the table around for the better.
News 
Market Data 
Discover 
